Introduction: This study aimed to determine and compare the effects of garlic tablets (Garcin(®)) and fluconazole on Candida vaginitis in women who presented to a health centre in Koohdasht, Iran, from August 2011 to March 2012.
Methods: The clinical trial was conducted on 110 married women (aged 18-44 years) who had complaints of itching or a burning sensation in the vaginal area. Candida vaginitis was diagnosed by pH measurement of vaginal secretions, direct microscopic evaluation and Sabouraud dextrose agar cultures of the vaginal discharge. On confirmation of diagnosis, the patients were randomly divided into two groups (n = 55). One group received 1,500 mg of Garcin tablets daily and the other received fluconazole tablets 150 mg daily, over a period of seven days. Four to seven days after the completion of treatment, patients were examined for treatment response and possible side effects.
Results: Complaints related to the disease improved by about 44% in the Garcin group and 63.5% in the fluconazole group (p < 0.05). The overall symptoms of the disease (i.e. redness of vulva and vagina, cheesy discharge, pustulopapular lesions and abnormal cervix) improved by about 60% in the Garcin group and 71.2% in the fluconazole group (p > 0.05). Results of microscopic evaluation and vaginal discharge culture showed significant differences before and after intervention in both groups (p < 0.05).
Conclusion: The present study shows that Garcin tablets could be a suitable alternative to fluconazole for the treatment of Candida vaginitis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613933 | PMC |
http://dx.doi.org/10.11622/smedj.2015153 | DOI Listing |
J Fungi (Basel)
December 2024
Graduate Institute of Biotechnology, National Chung Hsing University, Taichung 402, Taiwan.
Vulvovaginal candidiasis (VVC), a condition predominantly caused by , affects millions of women worldwide, prompting the need for alternative treatments due to the side effects and increasing resistance associated with conventional imidazole antifungals. This study investigated VAGINNE, a novel fermentation broth derived from species, as a potential VVC treatment. Using a BALB/c mouse model of infection, we evaluated VAGINNE's effects on vaginal microbiome composition, inflammatory markers, and tissue integrity.
View Article and Find Full Text PDFJ Fungi (Basel)
December 2024
Laboratorio de Micología Molecular, Unidad de Investigación Biomédica, Hospital Regional de Alta Especialidad de Ixtapaluca, Instituto Mexicano de Seguro Social para el Bienestar (IMSS-BIENESTAR), Carretera Federal México-Puebla Km 34.5, Ixtapaluca CP 56530, Mexico.
Vulvovaginal candidiasis (VVC) can lead to multiple complications when it occurs during pregnancy, so it is necessary to diagnose it promptly for effective treatment. Traditional methods for identifying spp. are often too time-consuming and have limited specificity and sensitivity.
View Article and Find Full Text PDFMicrobiol Spectr
January 2025
Clinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
The lack of clinical breakpoints and epidemiological cut-off values (ECOFFs) for antifungals prescribed for vulvovaginal candidiasis (VVC) make interpretation of antifungal susceptibility data difficult. This leads to empirical prescribing, poor clinical management and emergence of resistance. The susceptibilities of 152 , 105 , 31 and 8 VVC isolates against eight antifungals, were determined according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) E.
View Article and Find Full Text PDFVirulence
December 2025
Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, T he Netherlands.
Vulvovaginal candidiasis (VVC) is one of the most common infections caused by . VVC is characterized by an inadequate hyperinflammatory response and clinical symptoms associated with colonization of the vaginal mucosa. Compared to other host niches in which can cause infection, the vaginal environment is extremely rich in lactic acid that is produced by the vaginal microbiota.
View Article and Find Full Text PDFJ Am Acad Dermatol
January 2025
Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!